Summary

Psoriasis management in patients with cancer history or active malignancy poses challenges due to concerns about immunosuppressive therapies exacerbating cancer progression. This review synthesizes current evidence on treatment safety and efficacy, highlighting IL-17/IL-23 inhibitors as low-risk options, and the role of multi-disciplinary care. Key findings support individualized risk-benefit assessments, with newer biologics offering favorable safety profiles. Future research should address long-term outcomes and refine consensus recommendations.